Protagonist Therapeutics (PTGX) Operating Margin (2017 - 2025)
Protagonist Therapeutics' Operating Margin history spans 9 years, with the latest figure at 677.09% for Q4 2025.
- For Q4 2025, Operating Margin fell 75392.0% year-over-year to 677.09%; the TTM value through Dec 2025 reached 343.63%, down 40260.0%, while the annual FY2025 figure was 343.63%, 40184.0% down from the prior year.
- Operating Margin for Q4 2025 was 677.09% at Protagonist Therapeutics, up from 985.17% in the prior quarter.
- Across five years, Operating Margin topped out at 1001.21% in Q4 2023 and bottomed at 4824.56% in Q2 2022.
- The 5-year median for Operating Margin is 408.85% (2021), against an average of 662.33%.
- The largest annual shift saw Operating Margin tumbled -1525634bps in 2021 before it skyrocketed 103367bps in 2023.
- A 5-year view of Operating Margin shows it stood at 429.57% in 2021, then soared by 92bps to 32.46% in 2022, then surged by 3185bps to 1001.21% in 2023, then plummeted by -92bps to 76.84% in 2024, then plummeted by -981bps to 677.09% in 2025.
- Per Business Quant, the three most recent readings for PTGX's Operating Margin are 677.09% (Q4 2025), 985.17% (Q3 2025), and 758.04% (Q2 2025).